Literature DB >> 19121568

Doppler myocardial imaging compared to standard two-dimensional and Doppler echocardiography for assessment of diastolic function in patients with systemic amyloidosis.

Ghormallah B Al-Zahrani1, Diego Bellavia, Patricia A Pellikka, Angela Dispenzieri, Suzanne R Hayman, Jae K Oh, Chinami Miyazaki, Fletcher A Miller.   

Abstract

BACKGROUND AND AIMS: Cardiac amyloidosis (AL) is characterized by early impairment of diastolic function with preservation of systolic function, as assessed by standard measures, until very late in the disease process> Role of diastolic color Doppler myocardial imaging (cDMI), that is diastolic color Doppler myocardial velocity imaging (MVI) and strain rate imaging (SRI), to assess distolic dysfunction in this population remains unclear.
METHODS: 238 patients with biopsy proven systemic primary (AL) amyloidosis and 39 age and sex-matched controls have been enrolled. Left ventricular diastolic cDMI measures were compared in patients and healthy subjects, to test if such diastolic dysfunction occurs before longitudinal left ventricular systolic dysfunction.
RESULTS: Compared to Diastolic longitudinal, radial, and circumferential DMI, standard pulsed wave tissue Doppler imaging (PW-TDI) of the mitral annulus was the most accurate technique to detect early diastolic dysfunction in patients with AL. However, systolic longitudinal peak cDMI measures outperformed all of the diastolic measures, including PW-TDI, in separating patients with systemic AL, but no evidence of cardiac involvement on standard 2D and Doppler evaluation, from controls.
CONCLUSIONS: Even when compared to diastolic cDMI measurements, standard PW-TDI of the mitral annulus was the most accurate diastolic measure to detect early left ventricular dysfunction in patients with AL amyloidosis. However, no diastolic measure approached the accuracy of longitudinal systolic cDMI measurements in identifying ventricular dysfunction in AL patients with normal standard 2D and Doppler examinations, compared to controls.

Entities:  

Mesh:

Year:  2009        PMID: 19121568     DOI: 10.1016/j.echo.2008.11.013

Source DB:  PubMed          Journal:  J Am Soc Echocardiogr        ISSN: 0894-7317            Impact factor:   5.251


  11 in total

Review 1.  Echocardiographic evaluation of cardiac amyloid.

Authors:  Wendy Tsang; Roberto M Lang
Journal:  Curr Cardiol Rep       Date:  2010-05       Impact factor: 2.931

2.  Role of echocardiography in assessing cardiac amyloidoses: a systematic review.

Authors:  Jun Koyama; Masatoshi Minamisawa; Yoshiki Sekijima; Koichiro Kuwahara; Tsutomu Katsuyama; Kazutoshi Maruyama
Journal:  J Echocardiogr       Date:  2019-02-11

3.  Independent predictors of survival in primary systemic (Al) amyloidosis, including cardiac biomarkers and left ventricular strain imaging: an observational cohort study.

Authors:  Diego Bellavia; Patricia A Pellikka; Ghormallah B Al-Zahrani; Theodore P Abraham; Angela Dispenzieri; Chinami Miyazaki; Martha Lacy; Christopher G Scott; Jae K Oh; Fletcher A Miller
Journal:  J Am Soc Echocardiogr       Date:  2010-06       Impact factor: 5.251

Review 4.  Pathophysiology and treatment of cardiac amyloidosis.

Authors:  Morie A Gertz; Angela Dispenzieri; Taimur Sher
Journal:  Nat Rev Cardiol       Date:  2014-10-14       Impact factor: 32.419

5.  Utility of Doppler myocardial imaging, cardiac biomarkers, and clonal immunoglobulin genes to assess left ventricular performance and stratify risk following peripheral blood stem cell transplantation in patients with systemic light chain amyloidosis (Al).

Authors:  Diego Bellavia; Roshini S Abraham; Patricia A Pellikka; Angela Dispenzieri; John C Burnett; Ghormallah B Al-Zahrani; Tammy D Green; Michelle K Manske; Morie A Gertz; Fletcher A Miller; Theodore P Abraham
Journal:  J Am Soc Echocardiogr       Date:  2011-02-18       Impact factor: 5.251

Review 6.  [The various forms of left ventricular hypertrophy: diagnostic value of echocardiography].

Authors:  F Weidemann; S Störk; S Herrmann; G Ertl; M Niemann
Journal:  Herz       Date:  2011-12       Impact factor: 1.443

Review 7.  Practical recommendations for the diagnosis and management of transthyretin cardiac amyloidosis.

Authors:  Vasiliki Bistola; John Parissis; Emmanouil Foukarakis; Pipitsa N Valsamaki; Aris Anastasakis; Georgios Koutsis; Georgios Efthimiadis; Efstathios Kastritis
Journal:  Heart Fail Rev       Date:  2021-01-15       Impact factor: 4.214

8.  Predictive value of assessing diastolic strain rate on survival in cardiac amyloidosis patients with preserved ejection fraction.

Authors:  Dan Liu; Kai Hu; Stefan Störk; Sebastian Herrmann; Bastian Kramer; Maja Cikes; Philipp Daniel Gaudron; Stefan Knop; Georg Ertl; Bart Bijnens; Frank Weidemann
Journal:  PLoS One       Date:  2014-12-26       Impact factor: 3.240

Review 9.  Al amyloidosis.

Authors:  Estelle Desport; Frank Bridoux; Christophe Sirac; Sébastien Delbes; Sébastien Bender; Béatrice Fernandez; Nathalie Quellard; Corinne Lacombe; Jean-Michel Goujon; David Lavergne; Julie Abraham; Guy Touchard; Jean-Paul Fermand; Arnaud Jaccard
Journal:  Orphanet J Rare Dis       Date:  2012-08-21       Impact factor: 4.123

10.  Green tea halts progression of cardiac transthyretin amyloidosis: an observational report.

Authors:  Arnt V Kristen; Stephanie Lehrke; Sebastian Buss; Derliz Mereles; Henning Steen; Philipp Ehlermann; Stefan Hardt; Evangelos Giannitsis; Rupert Schreiner; Uwe Haberkorn; Philipp A Schnabel; Reinhold P Linke; Christoph Röcken; Erich E Wanker; Thomas J Dengler; Klaus Altland; Hugo A Katus
Journal:  Clin Res Cardiol       Date:  2012-05-15       Impact factor: 5.460

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.